Kalos Therapeutics Stengthens Executive Team
Novel therapeutic approval experience in related disease states
Phoenix, Arizona, October 14th, 2019 -- Kalos Therapeutics announced today that Jamie Jones has joined the company as their Chief Business Officer. In this role, Mr. Jones will provide strategic leadership from a commercial background as well as leadership in the evaluation, development, implementation, and management of partnerships, collaborations, and acquisitions. Mr. Jones will also serve as a member of Kalos Therapeutics' executive leadership team.
"Jamie is a recognized life science senior business leader who brings a commitment to patients and science to our organization. He has led the commercialization of novel best-in-class brands in diabetes, HIV and rare disease. During his 27-year career in pharma and biotech, Jamie has been a commercial leader for Novo Nordisk, Gilead Sciences and Alnylam Pharmaceuticals. Industry peers have recognized him as an inventive executive who challenges teams to overcome obstacles and breakthrough barriers by developing strong strategic relationships with corporate partners, community leaders, and stakeholders to ensure alliances are fully leveraged. Jamie's business and marketing capability will complement our executive leadership team's ability to maximize future assets." says George Colberg, Chairman and Co-Founder of Kalos Therapeutics, Inc.
Kalos Therapeutics is a pioneering biotech company developing a platform of drugs containing multiple arrays of natriuretic peptide which have demonstrated a broad spectrum of anti-tumor activity with negligible or no known adverse effects. In a Pre-IND Study using the parent drug involving a total of eighty-eight patients, including 22 healthy patients, the study demonstrated safety and therapeutic efficacy. Kalos' leading drug candidate, KTH 222, regulates cell growth via inhibition of the mitogen-activated protein kinase (MAPK) pathway. Kalos is changing the care paradigm for treating cancer patients as KTH 222 can function as a lead therapy or used in combination with existing therapies to improve efficacy and reduce toxicity and mitigate or reverse resistance. Nearly 17 million patients are living with a cancer diagnosis without safe nontoxic maintenance therapy. Kalos' therapeutic solutions expect to help stabilize these patients, allowing them time to recover and improve their quality of life while holding their tumors in a sustained state of slowed growth or stasis. Kalos' vision is to treat dangerous and debilitating diseases while improving the quality of life for patients and their families.
George Colberg CEO